Summary of Invention
Single wall nanotubes (SWNT) are inert, stable, flexible, non-toxic and non-immunogenic. They can be functionalized, that is, covalently bonded units can be added, making them soluble, and allowing them to carry targeting and therapeutic moieties. This invention is a method of treating a disease by administering soluble SWNTs functionalized with targeting moieties and payload molecules. The payload is delivered through the targeting moiety to the diseased cells where the payload has a therapeutic effect against the cells or elicits a therapeutic effect from the cells thereby treating the disease.
This invention discloses methods (1) to diagnose or locate a cancer, (2) to treat a cancer, or to elicit an immune response against a cancer or (3) to deliver an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT.
Advantages
- Soluble, non-toxic, non-immunogenic therapeutic and diagnostic constructs
- Enormous flexibility for key variables: targeting elements, payloads, solubility, other physical properties
- Disease-specific
- Many possible therapeutic routes
Area of Application
Therapeutic, diagnostic
Stage of Development
Animal studies
Lead Inventor
David Scheinberg, MD, PhD
Patent Information
U.S. patent application published: US2009/0304581
References
Escorcia FE, et al. (2007) Nanomed. Dec;2(6):805-15
Contact Information
Peter Fong, PhD
Manager, New Ventures and Business Development
fongp@mskcc.org
Tel: 646-227-7196; Fax: 212-557-8349
Stage of Development
Animal studies
